Clinical Trial Update: Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing aclidinium bromide and formoterol fumarate in moderate-to-severe COPD was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)
• FORMOTEROL FUMARATE (Formoterol fumarate dihydrate)

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: TERMINATED | Results posted: 2017-05-15